Author: ihub Studio

Terra Innovatum (NASDAQ:NKLR) is transforming the clean energy landscape with SOLO—the world’s first micro modular nuclear reactor set for commercial launch by 2028. Designed with a footprint of less than 100 square feet and fueled by a proven, decades-tested energy source, SOLO delivers unmatched safety, scalability, and simplicity. From residential communities to data centers, Terra…

Miami, United States, August 1st, 2025, FinanceWire Akasha, a newly emerging lifestyle brand rooted in creativity, intention, and innovation, has officially filed for federal trademark protection with the United States Patent and Trademark Office. The filing marks a key milestone in the brand’s strategic development as it expands its operations and e-commerce presence from its…

1. Apple Warned: GenAI Strategy Needed or Risk Falling Behind Needham has issued a stark warning about Apple’s (NASDAQ:AAPL) position in the generative AI race. Analyst Laura Martin cautioned that the company risks falling further behind rivals unless it outlines a clear GenAI strategy during its upcoming Q3 earnings. “We do not believe that Apple…

JPMorgan Chase (NYSE: JPM) analysts are noting a shift in the relationship between the U.S. dollar and global equities, suggesting the greenback may no longer serve as a strong diversifier for stock portfolios. In a recent note to clients, the bank highlighted a growing—though still modest—positive correlation between the weekly returns of the U.S. Dollar…

U.S. stocks moved up slightly on Monday morning as investors looked ahead to a busy week of second-quarter earnings reports, with major firms set to announce results. By 9:35 a.m. ET: Markets had stalled near record highs last Friday amid reports that President Trump is pushing for new tariffs of at least 15% to 20%…

July 21, 2025 — Helius Medical Technologies (NASDAQ:HSDT) saw its stock soar more than 70% in pre-market trading Monday after reporting strong clinical results for its Portable Neuromodulation Stimulator (PoNS) Stroke Registrational Program (SRP). The neurotechnology company announced that a double-blind, randomized clinical trial for the PoNS SRP successfully met its primary endpoint. The trial…

ProMIS Neurosciences Inc. (Nasdaq:PMN), a clinical-stage biotechnology firm specializing in treatments for neurodegenerative diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its lead therapeutic candidate, PMN310, for the treatment of Alzheimer’s disease (AD). PMN310 is a humanized monoclonal antibody designed to selectively target toxic oligomers of…